Development of novel radiolabeled tracers for in vivo targeting. Proteins (antibodies), peptides, small molecules and liposomes are labelled with various radionuclides such as 111In, 68Ga, 125I, 131I, 99mTc, 213Bi, 177Lu, 18F, for PET imaging, SPECT imaging or therapy. After successful production of the radiotracers, extensive in vitro characterization is performed. In vitro characterization includes stability tests and affinity and internalization characteristics using cells expressing the target of interest. The newly developed tracers are consecutively characterized for imaging and therapy studies in the field of oncology, diabetes, rheumatoid arthritis and neurology.